Search

Displaying results 2961 - 2970 of 4359 in total
  1. Drug

    mRNA-1010

    go.drugbank.com/drugs/DB22484
    Approved

    [L64058,L64060] It is administered as a single intramuscular dose. … the hemagglutinin (HA) glycoprotein of one influenza strain recommended for the season; after intramuscular injection, host cells translate the mRNA into HA proteins that the immune system recognizes as

  2. Drug

    DL-dimyristoylphosphatidylcholine

    go.drugbank.com/drugs/DB11283
    Approved

    A synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes. It is used in commercial drug preparations to solubilize drugs for injection

  3. Drug

    Omega-6 fatty acids

    go.drugbank.com/drugs/DB13168
    InvestigationalNutraceutical

    They are a family of fatty acid molecules that act as precursors to potent lipid mediator signalling molecules with either pro-inflammatory and anti-inflammatory effects. … Cells involved in the inflammatory response are typically rich in the n-6 fatty acid arachidonic acid, as generally, eicosanoids derived from n-6 PUFA are pro-inflammatory.

  4. Drug

    Zolmitriptan

    go.drugbank.com/drugs/DB00315
    ApprovedInvestigational

    Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)1B/1D/(1F) receptor agonists used to treat acute migraine. Sumatriptan was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. ...

    Products: ZOLMITRIPTAN DOC GENERICI, ZOLMITRIPTAN MYLAN GENERICS
  5. Drug

    Custirsen

    go.drugbank.com/drugs/DB05487
    Investigational

    Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells.

  6. Drug

    AGS-005

    go.drugbank.com/drugs/DB05741
    Experimental

    AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's

  7. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    Eladocagene exuparvovec is a recombinant adeno-associated virus-2 (AAV2)-based gene therapy that expresses human aromatic L-amino acid decarboxylase (AADC), and it is used to treat AADC deficiency, a fatal and rare genetic disorder that ...

  8. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  9. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    [A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients

    Synonyms: Immunoglobulin g1, anti-(human interleukin 5) (human-mus musculus monoclonal gsk3511294 .gamma.1-chain), disulfide with human-mus musculus monoclonal gsk3511294 .kappa.-chain, dimer
  10. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression